查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012800

适体市场：按类型、技术、应用和最终用户划分－2026-2030年全球市场预测

Aptamers Market by Type, Technology, Application, End-User - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年适体市值为 2.5435 亿美元，预计到 2025 年将成长至 2.8551 亿美元，复合年增长率为 12.43%，到 2030 年将达到 5.1377 亿美元。

主要市场统计数据
基准年 2024 2.5435亿美元
预计年份：2025年 2.8551亿美元
预测年份 2030 5.1377亿美元
复合年增长率 (%) 12.43%

利用高精度粘合剂在生命科学领域掀起适体革命：推动下一代诊断、治疗和安全解决方案的发展。

适体的出现开启了生命科学领域中分子辨识的革命性时代。与传统抗体不同，适体利用合成的核酸或胜肽结构，对多种标靶实现卓越的特异性和亲和性。这种精准的结合能力实现了前所未有的高度客製化，为诊断、治疗和环境监测等领域开闢了新的可能性。随着研究的活性化，适体的模组化特性使得结合基序的快速迭代和优化成为可能，从而能够适应新的生物标记和不断变化的疾病情况。

追踪适体开发领域的模式转移：重点介绍从传统筛选方法到高速、高通量分子辨识平台的进展

随着筛选调查方法和技术平台的演进，适体领域发生了翻天覆地的变化。传统的体外筛选过程正逐渐被更精细的方法所取代，这些方法能够缩短发现时间并提高结合特异性。微流体控系统的突破性进展使得连续流动筛选成为可能，且试剂消耗量极低；而高通量定序的整合则显着提高了候选适体库筛选的准确性。

检验2025 年美国提高关税对全球适体供应链、研究合作与市场动态的连锁反应。

2025年，美国对关键原料和设备加征关税，对全球适体生态系统产生了深远影响。修饰核苷酸和专用层析管柱等关键试剂面临成本上升的压力，迫使各机构重新评估其筹资策略和库存管理。新关税也影响了电泳系统和微流体装置等高精度设备的进口，而这些设备正是适体分选工作流程的基础。

根据类型、技术、应用和最终用户确定关键市场细分趋势，突显目标机会。

依类型进行市场细分可以明显看出核酸适体和胜肽适体之间的区别，二者各有其独特的优势。在核酸适体中，DNA适体具有优异的热稳定性和易于合成的特点，而RNA适体则展现出动态的二级结构，适用于辨识复杂的标靶。肽适体由短的胺基酸序列组成，具有更强的抗蛋白酶能力，并且能够识别核酸适体无法触及的独特抗原表位。

了解对美洲、欧洲、中东和非洲以及亚太地区适体市场的影响，并推动策略扩张重点。

凭藉着雄厚的研发资金、强大的生物技术基础和宽鬆的法规环境，美洲在适体创新领域持续保持主导地位。北美各地的关键中心促进了学术研究机构和商业开发人员之间的紧密合作，加速了基于适体的诊断和治疗方法向临床试验的转化。此外，各机构也建立了策略采购伙伴关係，确保能够在国内获得必要的试剂和设备。

介绍领先的适体创新者和策略参与者，他们透过专业平台、合作伙伴关係和技术投资来推动竞争差异化。

适体领域的领先创新者正透过专有技术和策略合作的协同效应来脱颖而出。一些专业供应商已建构了以高通量分选平台和化学修饰技术为核心的庞大智慧财产权组合，使其能够为复杂靶点提供客製化的结合解决方案。与製药公司的伙伴关係模式正在加速适体-药物偶联物和诊断检测方法的共同开发，从而缩短产品上市时间。

为产业领导者提供策略建议，以利用适体市场的演变：增强竞争力并建立协作生态系统

产业领导者应优先考虑建立多样化的适体筛选平台，以降低依赖单一技术所带来的风险。透过整合互补的调查方法，企业可以建构出针对不同标靶类别的药物发现工作流程，并加速候选化合物的筛选。同时，与多家区域供应商建立稳固的供应链合作关係，能够增强企业应对关税波动和物流中断的能力。

分析适体市场趋势所采用的严格调查方法详情：检验资料来源，确保分析的透明度和可靠性。

本分析的调查方法严谨地结合了第一手资料和第二手资料，以确保全面性和一致性。最初的第二手资料研究包括对科学文献、专利资料库、监管指南和白皮书的广泛查阅，以了解适体领域的历史趋势和新兴技术。此外，也利用专有资料库收集了关于筛选平台、修饰化学和应用开发的检验资讯。

本报告总结了对适体技术未来前景的策略见解，并强调了精准医疗和安全解决方案的必要性。

适体技术的演进正在革新分子识别领域，这些用途广泛的试剂被视为下一代诊断、治疗和安全解决方案的基础。调查方法和化学修饰方面的技术创新正在推动性能提升，而适应性供应链策略则有助于缓解关税波动等外部压力。市场区隔洞察凸显了在类型、技术和应用等维度上采取针对性策略的重要性，而区域分析则揭示了美洲、欧洲、中东和非洲以及亚太地区不同的成长轨迹。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：适体市场：依类型划分

  • 核酸适体
    • DNA适体
    • RNA适体
  • 胜肽适体

第九章 适体市场：依技术划分

  • SELEX 以外的技术
  • SELEX技术
    • 毛细管电泳 (CE) - SELEX
    • 捕获 SELEX
    • 塞勒克斯
    • 氧化石墨烯（GO）-SELEX
    • 微流体SELEX
    • 标准 SELEX

第十章 适体市场：依应用领域划分

  • 临床诊断
    • 心血管和代谢疾病的诊断
    • 遗传性和罕见疾病筛检
    • 感染疾病诊断
    • 神经系统疾病的诊断
    • 肿瘤诊断
  • 食品和环境安全
    • 农业检验
    • 环境监测
    • 食品安全检查
  • 治疗和药物开发
    • 心血管疾病
    • 感染疾病
    • 神经系统疾病
    • 肿瘤学
    • 罕见疾病和遗传疾病

第十一章 适体市场：依最终用户划分

  • 学术和研究机构
  • 医院和诊所
  • 製药和生物技术公司

第十二章 适体市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 适体市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 适体市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国适体市场

第十六章：中国适体市场

第十七章 竞争格局

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • 2bind GmbH
  • Agilent Technologies, Inc.
  • Aptadel Therapeutics SL
  • Aptagen, LLC
  • AptaMatrix, Inc.
  • Aptamer Group PLC
  • AptaTargets SL
  • AptusBiotech
  • Astellas Pharma Inc.
  • Base Pair Biotechnologies, Inc.
  • Basking Biosciences
  • Bio-Techne Corporation
  • Biogenes Technologies Sdn. Bhd.
  • Biotage
  • Cage Bio, Inc.
  • Creative Biogene
  • Creative Biolabs
  • Drive Therapeutics, LLC
  • F. Hoffmann-La Roche AG
  • Kaneka Eurogentec SA
  • NEC Corporation
  • NeoVentures Biotechnology Inc.
  • NOVAPTECH, SAS
  • Profacgen
  • SomaLogic, Inc.
  • TAGCyx Biotechnologies, Inc.
  • Veraptus
  • Vivonics Inc.
  • Zentek Ltd.
Product Code: MRR-4358BACA838E

The Aptamers Market was valued at USD 254.35 million in 2024 and is projected to grow to USD 285.51 million in 2025, with a CAGR of 12.43%, reaching USD 513.77 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 254.35 million
Estimated Year [2025] USD 285.51 million
Forecast Year [2030] USD 513.77 million
CAGR (%) 12.43%

Establishing the Aptamer Revolution in Life Sciences with Precision Binding Agents Fueling Next Generation Diagnostics Therapeutics and Safety Solutions

The advent of aptamers has ushered in a transformative era for molecular recognition in life sciences. Unlike traditional antibodies, aptamers leverage their synthetic nucleic acid or peptide structures to achieve exceptional specificity and affinity for a diverse array of targets. This precision binding capability has opened new doors for diagnostics, therapeutics, and environmental monitoring by offering a level of customization previously unattainable. As research intensifies, the modularity of aptamers enables rapid iteration of binding motifs to adapt to emerging biomarkers and evolving disease landscapes.

Moreover, the scalability of aptamer synthesis presents distinct advantages in manufacturing and cost management. The solid-phase synthesis of nucleic acid aptamers circumvents many constraints associated with biological production systems, streamlining quality control and reducing batch variability. Consequently, organizations are increasingly able to deploy aptamers in high-throughput screening contexts, facilitating accelerated discovery cycles.

The convergence of enhanced selection technologies with advanced chemical modification strategies further reinforces the role of aptamers as next-generation molecular tools. By integrating stability enhancements and functional conjugations, these molecules are primed to penetrate new application domains, setting the stage for unprecedented advancements in precision diagnostics and targeted therapies.

Tracking Paradigm Shifts in Aptamer Development Highlighting Advances from Traditional Selection Methods to Rapid High Throughput Molecular Recognition Platforms

The aptamer field has experienced seismic shifts as selection methodologies and technological platforms evolve. Traditional in vitro evolution processes have given way to refined approaches that accelerate discovery timelines and enhance binding specificity. Breakthroughs in microfluidic-based systems have minimized reagent consumption while enabling continuous flow selection, and the integration of high-throughput sequencing has drastically improved the resolution of candidate pools.

Concurrently, novel non-SELEX-based modalities have emerged to complement established procedures, offering alternative pathways for aptamer generation without the iterative cycles inherent to classical techniques. These complementary methods are fostering multidisciplinary collaborations, marrying principles of nanomaterials science, bioinformatics, and synthetic chemistry to refine aptamer performance.

Examining the Ripple Effects of Enhanced United States Tariffs in 2025 on Global Aptamer Supply Chains Research Collaborations and Market Dynamics

In 2025, the imposition of elevated tariffs by the United States on key raw materials and equipment has reverberated across the global aptamer ecosystem. Critical reagents such as modified nucleotides and specialized chromatography columns now face increased cost pressures, prompting organizations to reassess sourcing strategies and inventory management. The new tariffs have also affected the import of high-precision instrumentation, including electrophoresis units and microfluidic devices, which are foundational to aptamer selection workflows.

As a result, research institutions and commercial developers are exploring alternative supply channels and regional manufacturing partnerships to mitigate tariff-induced constraints. Some companies have begun forging agreements with domestic suppliers or diversifying vendor portfolios to maintain continuity of critical experiments. Furthermore, collaborative consortia are emerging to pool procurement power, sharing infrastructure and resources to offset elevated operational expenses.

These adaptive strategies underscore the importance of proactive trade and procurement planning. By carefully aligning supply chain configurations with regulatory landscapes, organizations can sustain research momentum and safeguard investment in long-term R&D initiatives despite fluctuating trade policies.

Unveiling Critical Market Segmentation Dynamics Based on Type Technology Application and End User to Illuminate Targeted Opportunities

Market segmentation by type reveals a clear bifurcation between nucleic acid aptamers and peptide aptamers, each offering distinct advantages. Within the nucleic acid category, DNA aptamers provide robust thermal stability and ease of synthesis, while RNA aptamers exhibit dynamic secondary structures well-suited for intricate target recognition. Peptide aptamers, constructed from short amino acid sequences, deliver enhanced protease resistance and can access unique epitopes inaccessible to nucleic acids.

From a technological perspective, the landscape divides into non-SELEX-based methodologies and SELEX technology. SELEX remains the cornerstone of aptamer discovery, with sophisticated variants including capillary electrophoresis-SELEX, which enables rapid separation of bound from unbound species, and capture-SELEX, where target immobilization streamlines selection. Cell-SELEX leverages live-cell environments to identify functionally relevant ligands, while graphene oxide-SELEX exploits π-π interactions to enrich high-affinity sequences. Microfluidic SELEX platforms integrate selection and amplification within nanoscale channels, and standard SELEX continues to serve as a reliable baseline methodology.

Applications span clinical diagnostics, food and environmental safety, and therapeutics and drug development. In clinical diagnostics, advancements in cardiovascular and metabolic disease screening, genetic and rare disease detection, infectious pathogen identification, neurological disorder analysis, and oncology biomarker assays are driving diagnostic innovation. Environmental and food safety applications encompass agricultural contaminant testing, ecosystem monitoring, and foodborne pathogen surveillance. Therapeutic pursuits target cardiovascular diseases, infectious agents, neurodegenerative disorders, cancer, and rare genetic conditions, highlighting aptamers' versatility.

End users range from academic and research institutions pioneering fundamental discoveries to hospital and clinical settings implementing diagnostic assays, as well as pharmaceutical and biotechnology companies integrating aptamer platforms into drug discovery and development pipelines.

Deciphering Regional Aptamer Market Influences across Americas Europe Middle East Africa and Asia Pacific Driving Strategic Expansion Priorities

The Americas continue to lead in aptamer innovation, underpinned by substantial R&D funding, robust biotechnology infrastructure, and a receptive regulatory environment. Key hubs across North America facilitate close collaboration between academic laboratories and commercial developers, driving rapid translation of aptamer-based diagnostics and therapeutics into clinical trials. Additionally, strategic procurement partnerships have emerged, enabling organizations to secure essential reagents and instrumentation domestically.

Europe Middle East and Africa exhibit a diverse landscape with harmonized regulatory frameworks supporting multi-country clinical studies. Significant investment in personalized medicine initiatives has accelerated diagnostic adoption, particularly within oncology and rare disease screening programs. Meanwhile, environmental monitoring directives across the European Union and adjacent regions are propelling the integration of aptamer-based sensors for pollutant and pathogen detection.

Asia-Pacific presents a fast-expanding market characterized by government-led innovation strategies, cost-effective manufacturing capabilities, and increasing local expertise in nucleic acid chemistry. Rapid urbanization and rising healthcare expenditures are driving demand for point-of-care diagnostics and affordable therapeutics. Collaborative partnerships between multinational corporations and regional biotech firms are emerging to establish production facilities and co-development centers, ensuring streamlined market entry and scale-up potential.

Profiling Leading Aptamer Innovators and Strategic Players Driving Competitive Differentiation through Specialized Platforms Collaborations and Technological Investments

Leading innovators in the aptamer sector have differentiated through the synergy of proprietary technologies and strategic alliances. Several specialist providers have built extensive intellectual property portfolios around high-throughput selection platforms and chemical modification techniques, enabling them to offer custom binding solutions for complex targets. Collaborative partnership models with pharmaceutical companies have facilitated co-development of aptamer-drug conjugates and diagnostic assays, accelerating time to market.

Investment in vertically integrated capabilities-spanning automated synthesis, rigorous quality control, and scalable production-has positioned these organizations to meet growing demand while maintaining stringent reproducibility standards. Meanwhile, cross-industry collaborations are increasingly common, with technology providers aligning with contract research organizations and academic centers to broaden application portfolios. By fostering open innovation networks and leveraging combined expertise, these key players are shaping the competitive dynamics of the aptamer market.

Outlining Strategic Recommendations for Industry Leaders to Capitalize on Aptamer Market Evolutions Enhance Competitive Positioning and Foster Collaborative Ecosystems

Industry leaders should prioritize diversification of aptamer selection platforms to mitigate the risks associated with single-technology dependency. By integrating complementary methodologies, organizations can tailor discovery workflows to diverse target classes and accelerate candidate identification. Simultaneously, establishing robust supply chain alliances with multiple regional suppliers will enhance resilience against tariff fluctuations and logistical disruptions.

Forging cross-sector partnerships with diagnostic manufacturers, pharmaceutical developers, and environmental testing laboratories will expand market reach and facilitate co-development of integrated solutions. Engaging early with regulatory authorities to define clear validation paths for aptamer-based products will streamline approval processes and reduce time to commercialization. In parallel, investing in automation and digital analytics-particularly machine learning algorithms for sequence optimization-will drive efficiency gains and elevate candidate quality.

Finally, companies should explore modular platform architectures that support flexible deployment across laboratory and field settings, ensuring that aptamer applications can adapt to emerging needs in point-of-care diagnostics, personalized therapeutics, and real-time environmental monitoring.

Detailing Rigorous Research Methodology Employed to Analyze Aptamer Market Trends Validate Data Sources and Ensure Analytical Transparency and Credibility

The research methodology underpinning this analysis combined a rigorous blend of primary and secondary approaches to ensure comprehensive coverage and analytical integrity. Initial secondary research involved extensive review of scientific literature, patent databases, regulatory guidelines, and white papers to map historical trends and emerging technologies in the aptamer domain. Proprietary databases were consulted to capture validated information on selection platforms, modification chemistries, and application deployments.

Primary research consisted of in-depth interviews with key stakeholders, including academic researchers, technical experts, procurement managers, and C-level executives across biotechnology and pharmaceutical organizations. These qualitative insights were supplemented with detailed case studies of successful product launches, collaborative research initiatives, and supply chain adaptations. Quantitative validation employed triangulation methods to cross-verify data points and identify consensus perspectives.

Throughout the process, data accuracy was reinforced through iterative consultations and peer reviews, ensuring that conclusions reflect both current industry realities and forward-looking projections. This systematic approach provides the transparency and credibility required to support strategic decision making in the rapidly evolving aptamer market.

Summarizing Strategic Insights into the Future Trajectory of Aptamer Technologies Reinforcing the Imperative for Precision Medical and Safety Solutions

The evolution of aptamer technologies is reshaping the landscape of molecular recognition, positioning these versatile agents as cornerstones of next-generation diagnostics, therapeutics, and safety solutions. Technological innovations in selection methodologies and chemical modifications are driving enhanced performance, while adaptive supply chain strategies are mitigating external pressures such as tariff shifts. Segmentation insights highlight the importance of targeted approaches across type, technology, and application dimensions, and regional analysis underscores varied growth trajectories in the Americas, EMEA, and Asia-Pacific.

Key players have distinguished themselves through strategic collaborations, IP development, and platform investments, setting the stage for intensified competition and accelerated commercialization. To navigate this dynamic environment, industry participants must pursue diversified technology portfolios, engage proactively with regulatory bodies, and foster cross-sector partnerships that leverage complementary expertise.

By aligning research priorities with market needs and deploying data-driven procurement and development frameworks, organizations can unlock the full potential of aptamers. This strategic alignment will be vital for driving innovation, achieving operational resilience, and securing leadership positions as the field continues to mature.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Aptamers Market, by Type

  • 8.1. Nucleic Acid Aptamers
    • 8.1.1. DNA Aptamers
    • 8.1.2. RNA Aptamers
  • 8.2. Peptide Aptamers

9. Aptamers Market, by Technology

  • 9.1. Non-SELEX-Based Technologies
  • 9.2. SELEX Technology
    • 9.2.1. Capillary Electrophoresis (CE)-SELEX
    • 9.2.2. Capture-SELEX
    • 9.2.3. Cell-SELEX
    • 9.2.4. Graphene Oxide (GO)-SELEX
    • 9.2.5. Microfluidic SELEX
    • 9.2.6. Standard SELEX

10. Aptamers Market, by Application

  • 10.1. Clinical Diagnostics
    • 10.1.1. Cardiovascular & Metabolic Disease Diagnostics
    • 10.1.2. Genetic & Rare Disease Screening
    • 10.1.3. Infectious Disease Diagnostics
    • 10.1.4. Neurological Disorder Diagnostics
    • 10.1.5. Oncology Diagnostics
  • 10.2. Food & Environmental Safety
    • 10.2.1. Agricultural Testing
    • 10.2.2. Environmental Monitoring
    • 10.2.3. Food Safety Testing
  • 10.3. Therapeutics & Drug Development
    • 10.3.1. Cardiovascular Diseases
    • 10.3.2. Infectious Diseases
    • 10.3.3. Neurological Disorders
    • 10.3.4. Oncology
    • 10.3.5. Rare & Genetic Disorders

11. Aptamers Market, by End-User

  • 11.1. Academic & Research Institutions
  • 11.2. Hospital & Clinics
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Aptamers Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Aptamers Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Aptamers Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Aptamers Market

16. China Aptamers Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2024
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2024
  • 17.3. Product Portfolio Analysis, 2024
  • 17.4. Benchmarking Analysis, 2024
  • 17.5. 2bind GmbH
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Aptadel Therapeutics SL
  • 17.8. Aptagen, LLC
  • 17.9. AptaMatrix, Inc.
  • 17.10. Aptamer Group PLC
  • 17.11. AptaTargets SL
  • 17.12. AptusBiotech
  • 17.13. Astellas Pharma Inc.
  • 17.14. Base Pair Biotechnologies, Inc.
  • 17.15. Basking Biosciences
  • 17.16. Bio-Techne Corporation
  • 17.17. Biogenes Technologies Sdn. Bhd.
  • 17.18. Biotage
  • 17.19. Cage Bio, Inc.
  • 17.20. Creative Biogene
  • 17.21. Creative Biolabs
  • 17.22. Drive Therapeutics, LLC
  • 17.23. F. Hoffmann-La Roche AG
  • 17.24. Kaneka Eurogentec S.A.
  • 17.25. NEC Corporation
  • 17.26. NeoVentures Biotechnology Inc.
  • 17.27. NOVAPTECH, S.A.S.
  • 17.28. Profacgen
  • 17.29. SomaLogic, Inc.
  • 17.30. TAGCyx Biotechnologies, Inc.
  • 17.31. Veraptus
  • 17.32. Vivonics Inc.
  • 17.33. Zentek Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 2. GLOBAL APTAMERS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL APTAMERS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL APTAMERS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 5. GLOBAL APTAMERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL APTAMERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 7. GLOBAL APTAMERS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL APTAMERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 9. GLOBAL APTAMERS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL APTAMERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 11. UNITED STATES APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 12. CHINA APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)

LIST OF TABLES

  • TABLE 1. GLOBAL APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 2. GLOBAL APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 3. GLOBAL APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. GLOBAL APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 7. GLOBAL APTAMERS MARKET SIZE, BY DNA APTAMERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL APTAMERS MARKET SIZE, BY DNA APTAMERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL APTAMERS MARKET SIZE, BY DNA APTAMERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL APTAMERS MARKET SIZE, BY RNA APTAMERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL APTAMERS MARKET SIZE, BY RNA APTAMERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL APTAMERS MARKET SIZE, BY RNA APTAMERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL APTAMERS MARKET SIZE, BY PEPTIDE APTAMERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL APTAMERS MARKET SIZE, BY PEPTIDE APTAMERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL APTAMERS MARKET SIZE, BY PEPTIDE APTAMERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL APTAMERS MARKET SIZE, BY NON-SELEX-BASED TECHNOLOGIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL APTAMERS MARKET SIZE, BY NON-SELEX-BASED TECHNOLOGIES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL APTAMERS MARKET SIZE, BY NON-SELEX-BASED TECHNOLOGIES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 20. GLOBAL APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 22. GLOBAL APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 24. GLOBAL APTAMERS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS (CE)-SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL APTAMERS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS (CE)-SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 26. GLOBAL APTAMERS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS (CE)-SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL APTAMERS MARKET SIZE, BY CAPTURE-SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 28. GLOBAL APTAMERS MARKET SIZE, BY CAPTURE-SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL APTAMERS MARKET SIZE, BY CAPTURE-SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 30. GLOBAL APTAMERS MARKET SIZE, BY CELL-SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL APTAMERS MARKET SIZE, BY CELL-SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 32. GLOBAL APTAMERS MARKET SIZE, BY CELL-SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL APTAMERS MARKET SIZE, BY GRAPHENE OXIDE (GO)-SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 34. GLOBAL APTAMERS MARKET SIZE, BY GRAPHENE OXIDE (GO)-SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL APTAMERS MARKET SIZE, BY GRAPHENE OXIDE (GO)-SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 36. GLOBAL APTAMERS MARKET SIZE, BY MICROFLUIDIC SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL APTAMERS MARKET SIZE, BY MICROFLUIDIC SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 38. GLOBAL APTAMERS MARKET SIZE, BY MICROFLUIDIC SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL APTAMERS MARKET SIZE, BY STANDARD SELEX, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 40. GLOBAL APTAMERS MARKET SIZE, BY STANDARD SELEX, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL APTAMERS MARKET SIZE, BY STANDARD SELEX, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 42. GLOBAL APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 43. GLOBAL APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 44. GLOBAL APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 45. GLOBAL APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 46. GLOBAL APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 47. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 48. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASE DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 49. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 50. GLOBAL APTAMERS MARKET SIZE, BY GENETIC & RARE DISEASE SCREENING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 51. GLOBAL APTAMERS MARKET SIZE, BY GENETIC & RARE DISEASE SCREENING, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 52. GLOBAL APTAMERS MARKET SIZE, BY GENETIC & RARE DISEASE SCREENING, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 53. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 54. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 55. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 56. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDER DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 57. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDER DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 58. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDER DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 59. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 60. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY DIAGNOSTICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 61. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 62. GLOBAL APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 63. GLOBAL APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 64. GLOBAL APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 65. GLOBAL APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 66. GLOBAL APTAMERS MARKET SIZE, BY AGRICULTURAL TESTING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 67. GLOBAL APTAMERS MARKET SIZE, BY AGRICULTURAL TESTING, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 68. GLOBAL APTAMERS MARKET SIZE, BY AGRICULTURAL TESTING, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 69. GLOBAL APTAMERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 70. GLOBAL APTAMERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 71. GLOBAL APTAMERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 72. GLOBAL APTAMERS MARKET SIZE, BY FOOD SAFETY TESTING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 73. GLOBAL APTAMERS MARKET SIZE, BY FOOD SAFETY TESTING, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 74. GLOBAL APTAMERS MARKET SIZE, BY FOOD SAFETY TESTING, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 75. GLOBAL APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 76. GLOBAL APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 77. GLOBAL APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 78. GLOBAL APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 79. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 80. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 81. GLOBAL APTAMERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 82. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 83. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 84. GLOBAL APTAMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 85. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 86. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 87. GLOBAL APTAMERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 88. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 89. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 90. GLOBAL APTAMERS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 91. GLOBAL APTAMERS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 92. GLOBAL APTAMERS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 93. GLOBAL APTAMERS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 94. GLOBAL APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 95. GLOBAL APTAMERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 96. GLOBAL APTAMERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 97. GLOBAL APTAMERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 98. GLOBAL APTAMERS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 99. GLOBAL APTAMERS MARKET SIZE, BY HOSPITAL & CLINICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 100. GLOBAL APTAMERS MARKET SIZE, BY HOSPITAL & CLINICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 101. GLOBAL APTAMERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 102. GLOBAL APTAMERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 103. GLOBAL APTAMERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 104. GLOBAL APTAMERS MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 105. AMERICAS APTAMERS MARKET SIZE, BY SUBREGION, 2018-2030 (USD THOUSAND)
  • TABLE 106. AMERICAS APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 107. AMERICAS APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 108. AMERICAS APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 109. AMERICAS APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 110. AMERICAS APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 111. AMERICAS APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 112. AMERICAS APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 113. AMERICAS APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 114. AMERICAS APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 115. NORTH AMERICA APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 116. NORTH AMERICA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 117. NORTH AMERICA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 118. NORTH AMERICA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 119. NORTH AMERICA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 120. NORTH AMERICA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 121. NORTH AMERICA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 122. NORTH AMERICA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 123. NORTH AMERICA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 124. NORTH AMERICA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 125. LATIN AMERICA APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 126. LATIN AMERICA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 127. LATIN AMERICA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 128. LATIN AMERICA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 129. LATIN AMERICA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 130. LATIN AMERICA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 131. LATIN AMERICA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 132. LATIN AMERICA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 133. LATIN AMERICA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 134. LATIN AMERICA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY SUBREGION, 2018-2030 (USD THOUSAND)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 145. EUROPE APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 146. EUROPE APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 147. EUROPE APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 148. EUROPE APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 149. EUROPE APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 150. EUROPE APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 151. EUROPE APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 152. EUROPE APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 153. EUROPE APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 154. EUROPE APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 155. MIDDLE EAST APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 156. MIDDLE EAST APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 157. MIDDLE EAST APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 158. MIDDLE EAST APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 159. MIDDLE EAST APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 160. MIDDLE EAST APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 161. MIDDLE EAST APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 162. MIDDLE EAST APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 163. MIDDLE EAST APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 164. MIDDLE EAST APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 165. AFRICA APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 166. AFRICA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 167. AFRICA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 168. AFRICA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 169. AFRICA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 170. AFRICA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 171. AFRICA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 172. AFRICA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 173. AFRICA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 174. AFRICA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 175. ASIA-PACIFIC APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 176. ASIA-PACIFIC APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 177. ASIA-PACIFIC APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 178. ASIA-PACIFIC APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 179. ASIA-PACIFIC APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 180. ASIA-PACIFIC APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 181. ASIA-PACIFIC APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 182. ASIA-PACIFIC APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 183. ASIA-PACIFIC APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 184. ASIA-PACIFIC APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 185. GLOBAL APTAMERS MARKET SIZE, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 186. ASEAN APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 187. ASEAN APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 188. ASEAN APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 189. ASEAN APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 190. ASEAN APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 191. ASEAN APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 192. ASEAN APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 193. ASEAN APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 194. ASEAN APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 195. ASEAN APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 196. GCC APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 197. GCC APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 198. GCC APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 199. GCC APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 200. GCC APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 201. GCC APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 202. GCC APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 203. GCC APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 204. GCC APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 205. GCC APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 206. EUROPEAN UNION APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 207. EUROPEAN UNION APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 208. EUROPEAN UNION APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 209. EUROPEAN UNION APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 210. EUROPEAN UNION APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 211. EUROPEAN UNION APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 212. EUROPEAN UNION APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 213. EUROPEAN UNION APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 214. EUROPEAN UNION APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 215. EUROPEAN UNION APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 216. BRICS APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 217. BRICS APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 218. BRICS APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 219. BRICS APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 220. BRICS APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 221. BRICS APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 222. BRICS APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 223. BRICS APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 224. BRICS APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 225. BRICS APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 226. G7 APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 227. G7 APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 228. G7 APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 229. G7 APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 230. G7 APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 231. G7 APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 232. G7 APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 233. G7 APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 234. G7 APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 235. G7 APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 236. NATO APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 237. NATO APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 238. NATO APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 239. NATO APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 240. NATO APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 241. NATO APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 242. NATO APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 243. NATO APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 244. NATO APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 245. NATO APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 246. GLOBAL APTAMERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 247. UNITED STATES APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 248. UNITED STATES APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 249. UNITED STATES APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 250. UNITED STATES APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 251. UNITED STATES APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 252. UNITED STATES APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 253. UNITED STATES APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 254. UNITED STATES APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 255. UNITED STATES APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 256. UNITED STATES APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
  • TABLE 257. CHINA APTAMERS MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 258. CHINA APTAMERS MARKET SIZE, BY TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 259. CHINA APTAMERS MARKET SIZE, BY NUCLEIC ACID APTAMERS, 2018-2030 (USD THOUSAND)
  • TABLE 260. CHINA APTAMERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 261. CHINA APTAMERS MARKET SIZE, BY SELEX TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 262. CHINA APTAMERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD THOUSAND)
  • TABLE 263. CHINA APTAMERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD THOUSAND)
  • TABLE 264. CHINA APTAMERS MARKET SIZE, BY FOOD & ENVIRONMENTAL SAFETY, 2018-2030 (USD THOUSAND)
  • TABLE 265. CHINA APTAMERS MARKET SIZE, BY THERAPEUTICS & DRUG DEVELOPMENT, 2018-2030 (USD THOUSAND)
  • TABLE 266. CHINA APTAMERS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)